Chiron, Corp., a leading player in the biotechnology sector, is headquartered in the United States and operates extensively across North America and Europe. Founded in the early 2000s, the company has achieved significant milestones, including advancements in therapeutic solutions and innovative drug development. Chiron, Corp. specialises in biopharmaceuticals, focusing on unique treatments for rare diseases and complex health conditions. Their core products are distinguished by cutting-edge research and a commitment to improving patient outcomes. With a strong market position, Chiron, Corp. has garnered recognition for its contributions to the industry, including partnerships with major healthcare institutions and a robust pipeline of promising therapies. The company continues to push the boundaries of science, making a meaningful impact in the lives of patients worldwide.
How does Chiron, Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Chiron, Corp.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Chiron, Corp., headquartered in the US, currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family relationship with Novartis AG, from which it inherits climate commitments and initiatives. Chiron's climate strategy is aligned with Novartis AG's sustainability goals, which include various initiatives such as the Science Based Targets initiative (SBTi), CDP, RE100, and the Climate Pledge. These initiatives aim to drive significant reductions in greenhouse gas emissions across the organisation. As a merged entity, Chiron benefits from Novartis AG's established climate commitments, although specific reduction targets for Chiron itself have not been disclosed. The cascading of data and initiatives from Novartis AG indicates a commitment to addressing climate change, although the exact scope of emissions (Scope 1, 2, or 3) and specific reduction achievements remain unspecified. In summary, while Chiron, Corp. does not provide direct emissions data, it is positioned within a framework of robust climate commitments inherited from Novartis AG, reflecting a broader industry trend towards sustainability and emissions reduction.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chiron, Corp. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.